In this article, we will take a look at the 14 Best Biotech Stocks to Buy Right Now.
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late. In particular, the Trump administration has disrupted the industry by reducing research funding, changing vaccine protocols, and supporting legislation to reduce Medicaid spending, among other policies.
Late September 25, President Trump fueled additional upheaval by threatening to put a 100% tariff on imported medications beginning October 1 unless the companies who manufacture them begin constructing plants in the United States.
Meanwhile, one of the most widely utilized analgesics, acetaminophen, commonly known as Tylenol, came under heightened scrutiny, as the FDA began updating its labeling on September 22 to alert consumers of the potential link between Tylenol use while pregnant and a higher likelihood of autism and ADHD in children.
Our Methodology
For our list of the best biotech stocks to buy right now, we started with a list of stocks pulled from ETFs, stock screeners, and web rankings. We then utilized Insider Monkey’s Q2 2025 database to discover the best stocks held by hedge funds. The list is organized in ascending order of hedge fund sentiment around each stock.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
14. CRISPR Therapeutics AG (NASDAQ:CRSP)
Number of Hedge Fund Holders: 26
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s collaboration with Sirius on FXI siRNA SRSD107, BMO Capital reaffirmed its Outperform rating and $75 price target on the company’s shares on September 23. The collaboration has resulted in the start of a Phase II trial for the prevention of venous thromboembolism (VTE), which does not include gene editing.
Clinical evidence from studies on atrial fibrillation (AF) and total knee arthroplasty (TKA) indicates that FXI is an appealing target that may upend the $15 billion thromboembolism market, which is currently dominated by medications that target Factor X.
About 40% of individuals with atrial fibrillation are either untreated or only partially treated, according to BMO Capital, which suggests an enormous demand for novel treatments in this area.
CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.
13. BeOne Medicines Ltd. (NASDAQ:ONC)
Number of Hedge Fund Holders: 28
BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best biotech stocks to buy. On September 18, Barclays began coverage of BeOne Medicines Ltd. (NASDAQ:ONC), rating it Overweight and setting a price target of $385 on the company’s shares. The firm cited two anticipated “value-inflecting pivotal data readouts” that might propel the oncology company’s growth.
The first projected catalyst is data on BeOne’s BTK inhibitor in first-line mantle cell lymphoma, which is due in the latter half of 2025. Barclays also mentioned that data in first-line gastroesophageal cancer for the company’s PD1 inhibitor with anti-HER2 mixture will come in the fourth quarter of 2025.
Another significant driver for BeOne Medicines Ltd. (NASDAQ:ONC), according to Barclays, is the significance of topline pivotal data for zanidatamab, with or without tislelizumab, in first-line gastroesophageal adenocarcinoma.
BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.
12.Summit Therapeutics Inc. (NASDAQ:SMMT)
Number of Hedge Fund Holders: 30
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best biotech stocks to buy. On September 16, H.C. Wainwright reaffirmed its $50 price target and Buy rating for Summit Therapeutics Inc. (NASDAQ:SMMT). The firm emphasized that Summit’s ivonescimab, a PD-1 x VEGF bispecific antibody, has accomplished clinical milestones that are unprecedented in PD-1 medicines, including improved results in the HARMONi-2 trial conducted in China.
H.C. Wainwright believes that investors now have a “highly risk-mitigated entry point” due to misconceptions about disclosure sequencing, regional variations in hazard ratios, and skepticism about multi-regional comparability.
The firm noted that HARMONi-2 overall survival and HARMONi-6 squamous non-small cell lung cancer outcomes, among other future data readouts expected by year-end 2025, might “reset the PD-1 landscape” and propel Summit’s stock price over all-time highs.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that specializes in creating novel medications for infectious and cancerous diseases.
11. Moderna, Inc. (NASDAQ:MRNA)
Number of Hedge Fund Holders: 39
Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc. (NASDAQ:MRNA)’s refrigerator-stable COVID-19 vaccine, Brookline Capital Markets reaffirmed its Buy rating and $198 price target for the company on September 23.
According to the new data, mNEXSPIKE/mRNA-1283 increased neutralizing antibodies against the LP.8.1 variant by an average of more than sixteen times, which Brookline regarded as “remarkably strong” when compared with Moderna’s initial COVID-19 vaccination and phase III registration results.
Brookline predicts that Moderna’s COVID-19 vaccine sales will total 10.9 million units in the United States this year, down from an expected 14.6 million in 2024, with possible global sales of $2.1 billion in 2025 and $15.6 billion by 2030.
Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company dedicated to the discovery, development, and commercialization of mRNA-based medicines and vaccines. The company received solid recognition for its COVID-19 vaccine, which was one of the first mRNA vaccines to be created and delivered worldwide.
10. Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Number of Hedge Fund Holders: 40
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025.
Benchmark’s revised price target depends on the biotechnology company’s projected 2025 revenues being 8.5 times higher. The firm also reported that Merck’s Keytruda Qlex, a subcutaneous formulation utilizing berahyaluronidase alpha-pmph, an enzyme licensed from Korean company Alteogen that rivals Halozyme’s Enhanze enzyme, was recently approved by the FDA.
Benchmark drew attention to the ongoing patent disputes about the formulation between the two companies.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that creates, manufactures, and sells drug-device combination solutions using advanced auto-injector technologies.
9. Incyte Corporation (NASDAQ:INCY)
Number of Hedge Fund Holders: 42
Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 to $81 on September 24. The firm attributed the change in part to growing interest in Incyte’s ‘989 CALR antibody program ahead of expected ASH (American Society of Hematology) updates.
While RBC Capital anticipates that key opinion leaders would want at least 30% spleen volume reduction for myelofibrosis (MF) combination therapy, the firm will be watching for sustained responses and deeper variant allele frequency (VAF) over time for essential thrombocythemia treatment.
Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer.
8. Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
Number of Hedge Fund Holders: 45
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best biotech stocks to buy. On September 24, Leerink Partners maintained its Outperform rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and raised its price target from $63 to $68. The boost comes after topline results for Ionis’ Alexander disease therapy, zilganersen.
Using the 10-meter walk test (10MWT), Leerink observed that Zilganersen showed a statistically significant improvement in stabilizing gait speed and steady gains across key secondary endpoints. The company’s valuation methodology for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) now includes a market model for Alexander disease.
While open-label extension data, though still years away, will offer more information about the treatment’s effect on life expectancy and disease progression, detailed results from the Zilganersen trial are anticipated at an upcoming medical conference.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) produces medications for serious medical conditions, with a specific emphasis on cardiovascular and neurological disorders.
7. Ascendis Pharma A/S (NASDAQ:ASND)
Number of Hedge Fund Holders: 45
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best biotech stocks to buy. UBS reaffirmed its 307 price target and Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) on September 23 in response to MBX’s clinical study for the treatment of persistent hypoparathyroidism.
Given Yorvipath’s higher placebo-adjusted response rates of 52.9% at 4 weeks and 69% at 26 weeks in its clinical trials, UBS maintains that Ascendis Pharma’s medication continues to lead the hypoparathyroidism treatment space, despite supportive rival data.
In what it considers to be a sizable market worth over $10 billion, UBS sees upside potential for Yorvipath sales both in the short and medium run and sees the MBX data release as relieving an overhang for Ascendis Pharma A/S (NASDAQ:ASND).
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.
6. Axsome Therapeutics Inc. (NASDAQ:AXSM)
Number of Hedge Fund Holders: 45
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best biotech stocks to buy. Following a recent discussion with the senior management at Axsome Therapeutics Inc. (NASDAQ:AXSM), Piper Sandler reiterated its Overweight rating on the company and set a price target of $148 on its shares. The firm learned about Axsome’s commercial support methods for Auvelity in major depressive disorder (MDD) and its possible extension into agitation associated with Alzheimer’s disease (AD-agitation).
With management anticipating a supplemental New Drug Application submission this quarter, Piper Sandler stated that Axsome’s sales and marketing expenditures will keep on rising, including workforce expansion tied to the expected label expansion for AD-agitation.
Despite rising costs, the firm expects strong operating leverage over time, owing to significant market possibilities in both MDD and AD-agitation, as well as attractive payer access to Auvelity in the MDD environment.
Axsome Therapeutics Inc. (NASDAQ:AXSM) is a clinical stage biopharmaceutical company that contributes to the creation of novel therapies for disorders of the central nervous system.
5. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Number of Hedge Fund Holders: 53
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best biotech stocks to buy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) participated in the Bank of America Global Healthcare Conference 2025 on September 23. During the conference, the company presented a strategic review of its robust pipeline, encompassing both encouraging advancements and possible barriers.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported that it has five phase 3 initiatives in progress and is focusing on commercial launches for LifTrak, Casgevy, and Jurnavix. Patients with cystic fibrosis have begun utilizing LifTrak at a rapid rate, especially those with uncommon mutations. Meanwhile, Jurnavix has addressed the need for non-opioid pain management by gaining widespread coverage in the United States.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) also expects to surpass its upper-end operating expense forecast of $5 billion in 2025. The company attributes this to investments in external innovation, improved marketing for Jurnavix, and quicker enrollment in clinical trials.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that is involved in the discovery and development of small-molecule medications for the treatment of severe illnesses, including cystic fibrosis.
4. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Number of Hedge Fund Holders: 58
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and raised its price target from $435 to $500, citing strong Amvuttra sales data.
According to the firm, August script data show that Amvuttra made $167 million in revenues, which represents a 17% increase from July, a 40% growth from June, and a 238% spike from February until the launch of cardiomyopathy (CM).
Amvuttra’s peak sales might reach $9.3 billion, according to RBC Capital, which increased its earlier estimate of $7.9 billion. In addition, the firm believes that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) could raise its TTR guidance by about $300 million, to about $2.5 billion.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a prominent biopharmaceutical company focused on RNA interference (RNAi) treatments, with a number of FDA-approved medications for rare genetic illnesses.
3. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Number of Hedge Fund Holders: 58
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby medication launch. The firm is optimistic about Attruby’s launch trajectory, citing a high number of new patient diagnoses.
According to UBS, Attruby has the potential to become a major product that generates over $4 billion in long-term revenue, which is bolstered by growing data showing how it differs from rival medication tafamidis.
In addition to highlighting BridgeBio’s pipeline beyond Attruby as “underappreciated,” the firm also pointed out that three Phase 3 readouts are expected within the next six months, which together might match Attruby’s revenue potential.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses.
2. Merus N.V. (NASDAQ:MRUS)
Number of Hedge Fund Holders: 58
Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform.
According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers.
With petosemtamab undergoing clinical derisking in head and neck malignancies and possible value creation in colorectal cancer through year-end 2026, the firm sees a substantial opportunity for share gain.
Merus NV (NASDAQ:MRUS) is a biotechnology company that develops antibody-based cancer treatments. It has several initiatives in the works, including Zenocutuzumab and Petosemtamab (MCLA-158).
1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Number of Hedge Fund Holders: 73
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE trial, which demonstrated that semaglutide and trevogrumab together preserved lean muscle mass while treating obesity with weight loss.
According to the 26-week trial, semaglutide by itself resulted in a 33% of weight loss to come from lean mass loss. In patients treated with semaglutide, around half of the muscle mass that would have been lost was preserved when trevogrumab, an anti-GDF8/anti-myostatin antibody, was introduced.
The study’s weight-loss phase results were reported at the European Association for the Study of Diabetes meeting. In the meantime, patients will continue in a weight maintenance phase through week 52.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.
While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
